Cerus Co. (NASDAQ:CERS) insider William Mariner Greenman sold 8,786 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $4.21, for a total transaction of $36,989.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cerus Co. (NASDAQ:CERS) traded down 0.71% during trading on Monday, hitting $4.18. 49,530 shares of the stock were exchanged. Cerus Co. has a 12-month low of $3.79 and a 12-month high of $7.64. The stock’s 50-day moving average price is $4.20 and its 200-day moving average price is $5.01. The firm’s market cap is $432.52 million.
Cerus (NASDAQ:CERS) last released its earnings results on Tuesday, March 7th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. The firm had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $11.29 million. Cerus had a negative net margin of 174.76% and a negative return on equity of 76.76%. Cerus’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.15) EPS. On average, equities analysts expect that Cerus Co. will post ($0.61) EPS for the current year.
Your IP Address:
Several brokerages have issued reports on CERS. Zacks Investment Research downgraded shares of Cerus from a “hold” rating to a “sell” rating in a report on Thursday, January 5th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of Cerus in a report on Friday, March 10th. FBR & Co reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Cerus in a report on Thursday, December 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $9.00 price objective on shares of Cerus in a research report on Wednesday, March 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.25.
Institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP bought a new position in Cerus during the third quarter valued at approximately $81,061,000. Peregrine Capital Management LLC bought a new position in Cerus during the third quarter valued at approximately $20,642,000. Senvest Management LLC boosted its position in Cerus by 51.2% in the third quarter. Senvest Management LLC now owns 2,411,336 shares of the company’s stock valued at $14,974,000 after buying an additional 816,676 shares during the last quarter. Norges Bank bought a new position in Cerus during the fourth quarter valued at approximately $3,407,000. Finally, ARK Investment Management LLC bought a new position in Cerus during the fourth quarter valued at approximately $2,879,000. 68.91% of the stock is currently owned by hedge funds and other institutional investors.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/william-mariner-greenman-sells-8786-shares-of-cerus-co-cers-stock/1708905.html
Receive News & Ratings for Cerus Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Co. and related companies with MarketBeat.com's FREE daily email newsletter.